Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID 4499155
Author(s) Leuppi-Taegtmeyer, Anne; Duthaler, Urs; Hammann, Felix; Schmid, Yasmin; Dickenmann, Michael; Amico, Patricia; Jehle, Andreas W.; Kalbermatter, Stefan; Lenherr, Christoph; Meyer Zu Schwabedissen, Henriette E.; Haschke, Manuel; Liechti, Matthias E.; Krähenbühl, Stephan
Author(s) at UniBasel Liechti, Matthias Emanuel
Meyer zu Schwabedissen, Henriette
Year 2019
Title Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions
Journal Nephrology, Dialysis, Transplantation
Volume 34
Number 4
Pages / Article-Number 692-702
Mesh terms Adult; Aged; Analgesics, Opioid, pharmacokinetics; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic, therapy; Kidney Function Tests; Male; Middle Aged; Morphinans, pharmacokinetics; Naloxone, pharmacokinetics; Narcotic Antagonists, pharmacokinetics; Oxycodone, pharmacokinetics; Oxymorphone, pharmacokinetics; Prognosis; Renal Dialysis, methods; Tissue Distribution
Abstract The pharmacokinetics of oxycodone in patients with end-stage renal disease (ESRD) requiring haemodialysis are largely unknown. Therefore, we investigated the pharmacokinetics of oxycodone/naloxone prolonged release and their metabolites in patients with ESRD during and between haemodialysis sessions.; Single doses of oxycodone/naloxone (5/2.5 or 10/5 mg) were administered in nine patients with ESRD using a cross-over design on the day of dialysis and on a day between dialysis sessions. Plasma, dialysate and urine concentrations of oxycodone, naloxone and their metabolites were determined up to 48 h post-dosing using a liquid chromatography-tandem mass spectrometry system.; Haemodialysis performed 6-10 h after dosing removed ∼10% of the administered dose of oxycodone predominantly as unconjugated oxycodone and noroxycodone or conjugated oxymorphone and noroxymorphone. The haemodialysis clearance of oxycodone based on its recovery in dialysate was (mean ± SD) 8.4 ± 2.1 L/h. The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis. Plasma levels of the active metabolite oxymorphone in its unconjugated form were very low.; Oxycodone is removed during haemodialysis. The pharmacokinetics including the relatively short half-life of oxycodone in patients with ESRD with or without haemodialysis and the absence of unconjugated active metabolites indicate that oxycodone can be used at usual doses in patients requiring dialysis.
Publisher Oxford University Press
ISSN/ISBN 0931-0509 ; 1460-2385
Full Text on edoc Restricted
Digital Object Identifier DOI 10.1093/ndt/gfy285
PubMed ID
Document type (ISI) Journal Article, Randomized Controlled Trial

MCSS v5.8 PRO. 0.328 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |